Pieter Julien Luc De Visschere

Prof. Dr. Pieter Julien Luc De Visschere

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in European Urology Oncology
Verified
Journal Article
Closed access
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
CSChloë Standaert
Chloë Standaert
JFJurgen J. Fütterer
Jurgen J. Fütterer
GVGeert M. Villeirs
Geert M. Villeirs
VPValeria Panebianco
Valeria Panebianco
SFStefano Fanti
Stefano Fanti

1 January 2017 in Clinical Radiology
Verified
Journal Article
Closed access
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
NLN. Lumen
N. Lumen
POP. Ost
P. Ost
KDK. Decaestecker
K. Decaestecker
EPE. Pattyn
E. Pattyn
GVG. Villeirs
G. Villeirs

1 June 2010 in American Journal of Roentgenology
Verified
Journal Article
Closed access
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
GMGert O. De Meerleer
Gert O. De Meerleer
JFJurgen J. Fütterer
Jurgen J. Fütterer
GVGeert M. Villeirs
Geert M. Villeirs
OBJECTIVE. In patients with clinically suspected local recurrence of prostate cancer, a lobulated hyperintense mass in the radical prostatectomy fossa can be readily visualized with T2-weighted MRI, but this imaging technique is less successful after treatments such as radiation therapy, high-intensity focused ultrasound, and cryosurgery. We describe the additional value of functional techniques in the assessment of local recurrence.CONCLUSION. The use of functional MRI techniques such as MR spectroscopy, diffusion-weighted imaging, and dynamic contrast-enhanced MRI has shown promise in increasing overall imaging performance in the detection of local recurrence.

3 July 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
LNLeslie Naesens
Leslie Naesens
LLLouis Libbrecht
Louis Libbrecht
CPCharles Van Praet
Charles Van Praet
NLNicolaas Lumen
Nicolaas Lumen
GVGeert Villeirs
Geert Villeirs

4 August 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
AVAnne Vral
Anne Vral
GPGianpaolo Perletti
Gianpaolo Perletti
EPEva Pattyn
Eva Pattyn
MPMarleen Praet
Marleen Praet
GVGeert M. Villeirs
Geert M. Villeirs

4 February 2016 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
Pieter Julien Luc De VisscherePieter Julien Luc De Visschere
Pieter Julien Luc De Visschere
ABAlberto Briganti
Alberto Briganti
JFJurgen J. Fütterer
Jurgen J. Fütterer
PGPirus Ghadjar
Pirus Ghadjar
HIHendrik Isbarn
Hendrik Isbarn
GVGeert M. Villeirs
Geert M. Villeirs
Most prostate cancers (PC) are currently found on the basis of an elevated PSA, although this biomarker has only moderate accuracy. Histological confirmation is traditionally obtained by random transrectal ultrasound guided biopsy, but this approach may underestimate PC. It is generally accepted that a clinically significant PC requires treatment, but in case of an non-significant PC, deferment of treatment and inclusion in an active surveillance program is a valid option. The implementation of multiparametric magnetic resonance imaging (mpMRI) into a screening program may reduce the risk of overdetection of non-significant PC and improve the early detection of clinically significant PC. A mpMRI consists of T2-weighted images supplemented with diffusion-weighted imaging, dynamic contrast enhanced imaging, and/or magnetic resonance spectroscopic imaging and is preferably performed and reported according to the uniform quality standards of the Prostate Imaging Reporting and Data System (PIRADS). International guidelines currently recommend mpMRI in patients with persistently rising PSA and previous negative biopsies, but mpMRI may also be used before first biopsy to improve the biopsy yield by targeting suspicious lesions or to assist in the selection of low-risk patients in whom consideration could be given for surveillance.